Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Core Viewpoint - Madrigal Pharmaceuticals has entered into an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, enhancing its position in the development of therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][4]. Company Developments - The agreement allows Madrigal to develop, manufacture, and commercialize ervogastat, along with rights to two additional early-stage MASH pipeline assets. Pfizer received an upfront payment of $50 million, with potential additional payments and royalties based on net sales [4]. - Madrigal plans to present further details at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [2][5]. Product Information - Ervogastat is a liver-directed oral DGAT-2 inhibitor that lowers hepatic triglycerides and reduces liver inflammation. In a Phase 2 study, 72% of patients achieved at least a 30% reduction in liver fat, and 61% achieved at least a 50% reduction [3][4]. - The combination of ervogastat with Madrigal's existing product, Rezdiffra, is expected to provide additive therapeutic benefits due to their complementary mechanisms of action [3][5]. Industry Context - MASH is a serious liver disease that can lead to severe complications, including cirrhosis and liver cancer. It is the leading cause of liver transplantation in women in the U.S. and is increasingly recognized as a significant health issue [6][7]. - As awareness of MASH increases, the number of diagnosed patients with moderate to advanced fibrosis is expected to grow, highlighting the need for effective treatment options [8].